Ubs Asset Management Americas Inc Magenta Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.07 - $9.89 $69,756 - $113,655	-11,492 Reduced 2.2%	511,542 $3.72 Million
Q2 2021 Aug 16, 2021	SELL	$9.76 - $14.15 $372,568 - $540,147	-38,173 Reduced 6.8%	523,034 $5.12 Million
Q1 2021 May 14, 2021	BUY	$7.66 - $13.38 $27,116 - $47,365	3,540 Added 0.63%	561,207 $6.64 Million
Q4 2020 Mar 01, 2021	SELL	$6.1 - $7.94 $316,620 - $412,125	-51,905 Reduced 8.51%	557,667 $4.37 Million
Q3 2020 Nov 13, 2020	BUY	$6.52 - $8.94 $62,409 - $85,573	9,572 Added 1.6%	609,572 $4.15 Million
Q2 2020 Aug 14, 2020	BUY	$6.18 - $10.76 $3.71 Million - $6.46 Million	600,000 New	600,000 $4.51 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.